Back to search results

Extension Study of Atumelnant for Congenital Adrenal Hyperplasia

This study is an extension to evaluate the long-term safety and effectiveness of atumelnant (CRN04894) for individuals with Congenital Adrenal Hyperplasia (CAH). Atumelnant works by blocking the melanocortin 2 receptor (MC2R), which is involved in how your body responds to stress hormones. You can join this study if you are between 16 and 74 years old, have CAH, and have already completed a previous Crinetics atumelnant CAH study. The main goals are to track any side effects, including serious ones like adrenal insufficiency, and to see if the medication helps reduce hospitalizations related to CAH over 108 weeks. The study aims to enroll about 200 participants.

Study design
This is a single-arm, open-label study, meaning all participants will receive atumelnant and everyone involved will know what treatment is being given. It plans to enroll approximately 150 to 200 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 108 weeks to monitor for side effects and other health events.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06712823

An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia

Recruiting
PHASE2Ages 16–74InterventionalTreatment
Crinetics Pharmaceuticals Inc.
~200 participants
Updated 2026-06-29 on ClinicalTrials.gov
What's tested:atumelnant (CRN04894)

At a glance

Recruiting sites
10 of 13 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of treatment-emergent adverse events (TEAEs), including treatment-emergent serious adverse events (SAEs), adverse events of special interest (AESI [adrenal insufficiency]) and any adverse events (AEs) leading to discontinuation
Measured over Week 108
+3 more outcomes measured

Conditions

Congenital Adrenal Hyperplasia
Classic Congenital Adrenal Hyperplasia

Explore related trials

Classic Congenital Adrenal HyperplasiaCongenital Adrenal Hyperplasia

NCT06712823

Where you'd take part

This study runs at 13 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Crinetics Study Site

    Córdoba, Córdoba Province, Argentinano site contact published

    Recruiting

  • Crinetics Study Site

    Curitiba, Paraná, Brazilno site contact published

    Recruiting

  • Crinetics Study Site

    Porto Alegre, Rio Grande do Sul, Brazilno site contact published

    Recruiting

  • Crinetics Study Site

    Botucatu, São Paulo, Brazilno site contact published

    Recruiting

  • Crinetics Study Site

    Rio de Janeiro, Brazilno site contact published

    Recruiting

  • Crinetics Study Site

    São Paulo, Brazilno site contact published

    Recruiting

  • Crinetics Study Site

    Munich, Bavaria, Germanyno site contact published

    Recruiting

  • Crinetics Study Site

    Roma, Italyno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Crinetics Clinical Trials
[email protected]
833-827-9741
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence of treatment-emergent adverse events (TEAEs), including treatment-emergent serious adverse events (SAEs), adverse events of special interest (AESI [adrenal insufficiency]) and any adverse events (AEs) leading to discontinuationWeek 108
  • Incidence of glucocorticoid (GC) deficiency / adrenal insufficiency and adrenal crisisWeek 108
  • Incidence of hospitalizations related to congenital adrenal hyperplasia (CAH)Week 108
  • Change from baseline in morning (before 11:00 AM) serum androstenedione (A4) over timeWeek 108